Dexcom stock price traded around $123

Dexcom stock price traded around $123.45 today, reflecting a 1.8% intraday gain as investor sentiment improved following strong Q1 earnings. Analysts cite growing continuous glucose monitoring (CGM) adoption trends as a long-term bullish driver in the medtech sector. Some firms, like J.P. Morgan, have reiterated an overweight rating and recently raised their price target to $112. These analysts highlight the current stock levels as an attractive opportunity, given DexCom’s guidance and execution quality, while acknowledging some near-term valuation risks. Total revenues grew 15.2% (15% on an organic basis) to $1.16 billion year over year. Sales beat the Zacks Consensus Estimate by 3.1%. The year-over-year revenue growth was driven by continued strong category demand, focused execution and a growing contribution from recent access wins, especially for type 2 diabetes. Dexcom stock price settled at $122.60 on moderate volume trading. Market sentiment remains positive due to stable operational cash flow and strong pipeline innovation.